Multi-ingredient senolytic blend,
does it really help with Clearance of senescent cells, tissue rejuvenation, and extension of healthspan?
research showsNo clinical efficacy literature directly testing whether a Qualia-type finished product clears senescent cells, rejuvenates tissue, or extends healthspan in humans was identified, so the grade is ?. A 2026 finished-product study measured only blood proteins after seven days; all four prespecified SASP proteins were nonsignificant. Ingredient, animal, and dasatinib-plus-quercetin findings cannot be transferred to this supplement blend.
ads claimCell experiments and animal-lifespan findings for multiple polyphenols are combined into claims of 'senescent-cell cleanup,' 'full-body reset,' 'rejuvenation,' and 'longer healthspan.' A blend is not guaranteed to equal the sum of findings for its individual ingredients.
Useful facts when choosing a product
- Finished products such as Qualia Senolytic are available in South Korea mainly through cross-border or online sellers and promote six capsules daily for two consecutive days each month, twelve capsules total.
- The formula contains numerous ingredients such as fisetin, quercetin phytosome, curcumin, luteolin, and piperlongumine; composition and dose vary among products.
- The 2026 study assessed proteins seven days after a two-day exposure and does not establish long-term safety or clinical healthspan.
What the research actually shows
Blomquist 2026 compared 48 blood proteins at baseline and day seven after two days of Qualia Senolytic. Sixty-nine participants received the product and 53 had paired protein data in an open-label, uncontrolled study. All four prespecified SASP proteins were null, and exploratory changes did not survive multiple-comparison correction. Hickson 2019 studied nine patients receiving prescription dasatinib plus high-dose quercetin, while healthspan findings for fisetin in Yousefzadeh 2018 were mainly in mice.
Why this is classified as ?
Absence of direct human efficacy literature requires ?, and indirect preclinical or ingredient evidence plus null primary surrogates was not converted into D or C.
Counterpoint. A preregistered controlled trial directly measuring senescent-cell burden and tissue function could make grading possible.
Rejudgment record. New verdict — No direct human efficacy literature tests senescent-cell clearance, tissue rejuvenation, or healthspan for the finished product
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Clearance of senescent cells | ? | No controlled efficacy trial directly measured human senescent-cell burden for the finished product. |
| Tissue rejuvenation | ? | No finished-product study tested tissue function or rejuvenation as a clinical endpoint. |
| Extension of healthspan | ? | No finished-product literature assessed human healthspan, functional decline, or disease incidence. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Blomquist SA et al. 2026 | Open-label, uncontrolled exploratory proteomics study | 53 | Funded, designed, and analyzed by Qualia with multiple affiliated authors | Forty-eight blood proteins at day seven, including four prespecified SASP proteins | Prespecified TNF, IL-1 beta, CXCL8, and VEGFA were all null; exploratory signals did not survive multiple-comparison correction. | Key but indirect |
| Hickson LJ et al. 2019 | Open-label, single-arm prescription-drug combination pilot | 9 | Public and foundation support; unrelated to the finished product | Adipose and skin senescence markers | Markers decreased after dasatinib plus quercetin; this different drug combination cannot be transferred to the finished product. | Indirect |
| Yousefzadeh MJ et al. 2018 | Preclinical senolytic study | Public research funding | Senescence markers, healthspan, and lifespan | Fisetin produced a healthspan signal in mice; this is not clinical efficacy of the human blend. | Preclinical |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-17).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-17 · Corrections: none
Cite this verdict
[Chamgap] Multi-ingredient senolytic blend x clearance of senescent cells, tissue rejuvenation, and extension of healthspan — Evidence Grade ?. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/antioxidant-aging/multi-ingredient-senolytic-blend-healthspan/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.